GMALL-EVOLVE

Hematological neoplasms
Acute lymphoblastic leukemia
First-Line-Therapy (Metastatic Disease/Hematology)
Ph+ ALL, ponatinib compared to imatinib in combination with low-intensity chemotherapy, to compare end of therapy with indication for SCT with TKI in combination with blinatumomab and chemotherapy in optimal response and to assess blinatumomab before SCT in suboptimal response
Ph+ ALL, ponatinib compared to imatinib in combination with low-intensity chemotherapy, to compare end of therapy with indication for SCT with TKI in combination with blinatumomab and chemotherapy in optimal response and to assess blinatumomab before SCT in suboptimal response